MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism

Loading news article.

MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism | WAPE

MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism

Article summary

Related companies

Comments —